ライフサイエンスコーパス: matrix metalloproteinase 9

1 n in syndecan-1, increase in heparanase, and matrix metalloproteinase 9).

2 ing expression of macrophage-specific MMP-9 (matrix metalloproteinase-9).

3 asion (intercellular adhesion molecule-1 and matrix metalloproteinase-9).

4 flammation (cyclooxygenase-2), and invasion (matrix metalloproteinase-9).

5 trix metalloproteinase-12) and gelatinase B (matrix metalloproteinase-9).

6 obial peptides (RegIIIbeta, RegIIIgamma) and matrix metalloproteinase 9.

7 ture NGF (mNGF) and that mNGF is degraded by matrix metalloproteinase 9.

8 h factor, platelet-derived growth factor, or matrix metalloproteinase 9.

9 stress fibers, and reduce the expression of matrix metalloproteinase 9.

10 press CHIT activity and enhance secretion of matrix metalloproteinase 9.

11 ed to reduction of their levels of CD62L and matrix metalloproteinase-9.

12 This increase was independent of matrix metalloproteinase-9.

13 ation of myeloid cells expressing S100A8 and matrix metalloproteinase-9.

14 progression possibly in part by stabilizing matrix metalloproteinase-9.

15 of the NF-kappaB target genes IL-8, IL-6 and matrix metalloproteinase-9.

16 tic, express macrophage markers, and secrete matrix metalloproteinase-9.

17 ial activation, and microglial expression of matrix metalloproteinase-9.

18 nd that deletion of macrophage LRP increases matrix metalloproteinase-9.

19 nism involving the PI3K/AKT/mTOR pathway and matrix metalloproteinase-9.

20 n in stem cells in vivo and in vitro through matrix metalloproteinase-9.

21 minin, and insoluble elastin, as potently as matrix metalloproteinase-9.

22 0), kallikrein (0.73), lipoprotein a (1.29), matrix metalloproteinase 9 (1.30), the interaction term

23 .9 vs 3753.2 +/- 1106.0 pg/mL, P = .03), and matrix metalloproteinase-9 (101 515.6 +/- 37 088.4 vs 14

24 d), tissue plasminogen activator (2.7-fold), matrix metalloproteinase-9 (4.1-fold), and Factor Xa (3.

25 lycosaminoglycans, lysosomal hydrolases, and matrix metalloproteinase 9, a known modulator of Lyme ar

26 amphiregulin, a growth factor that regulates matrix metalloproteinase-9; a shift in transforming grow

27 as myeloperoxidase, neutrophil elastase, and matrix metalloproteinase 9, activates macrophages throug

28 n degradation by inhibiting plasmin-mediated matrix metalloproteinase 9 activation.

29 mmatory models, and was sufficient to reduce matrix metalloproteinase-9 activation and macrophage rec

30 nhibits plasminogen activation and regulates matrix metalloproteinase-9 activation and macrophage rec

31 treatment reduced intravasation by reducing matrix metalloproteinase-9 activities.

32 han ROS neutralization resulted in decreased matrix metalloproteinase 9 activity as well as loss of m

33 r-1, and an associated threefold increase in matrix metalloproteinase 9 activity compared with LCWE a

34 ereas the latter was associated with reduced matrix metalloproteinase 9 activity.

35 In addition, PKal inhibition reduced matrix metalloproteinase-9 activity in brain following s

36 Importantly, neutralization of matrix metalloproteinase-9 activity in Ceacam1(-/-) mice

37 tumor formation and metastasis with reduced matrix metalloproteinase-9 activity in the blood.

38 For murine macrophages, matrix metalloproteinase-9 activity was found to be requ

39 -induced migratory responsiveness, decreased matrix metalloproteinase-9 activity, and increased neuro

40 ACS-1 also inhibited matrix metalloproteinase-9 activity, cellular migration,

41 Matrix metalloproteinase 9 and 13 expression and matrix

42 Lung matrix metalloproteinase 9 and 2 activities increased, w

43 ed that PKC similarly regulated secretion of matrix metalloproteinase 9 and chitinase-3-like-1 protei

44 increased levels and activity of circulating matrix metalloproteinase 9 and elevated angiostatin leve

45 elastase) and selected inflammatory markers (matrix metalloproteinase 9 and interleukin [IL]-17).

46 It is a major inducer of matrix metalloproteinase 9 and is selectively toxic for

47 lease of the granules' contents, measured as matrix metalloproteinase 9 and neutrophil elastase activ

48 (a precursor of peroxide that activates pro-matrix metalloproteinase 9 and osteogenic signaling in v

49 ling of epidermal growth factor receptor and matrix metalloproteinase 9 and resulted in suppression o

50 activin A and GM-CSF; and metalloproteinases matrix metalloproteinase-9 and a disintegrin and metallo

51 P-1alpha/CCL3, MIP-1beta/CCL4, MCP-1/CCL-2), matrix metalloproteinase-9 and cell death regulators (Fa

52 -xL, cFLIP, cIAP-1, and survivin), invasion (matrix metalloproteinase-9 and intercellular adhesion mo

53 ls with CLS in SAT exhibited upregulation of matrix metalloproteinase-9 and monocyte antigen CD14 gen

54 peptides and Bhsp65, and of the activity of matrix metalloproteinase-9 and phospho-ERK.

55 nt, including increases in the following: i) matrix metalloproteinase-9 and proinflammatory mediator

56 hase (eNOS) and 2 targets of eNOS signaling, matrix metalloproteinase-9 and soluble Kit ligand.

57 n of Wiskott-Aldrich syndrome protein (WASP)/matrix metalloproteinase-9 and the degradation of matrix

58 lueberry treatment decreased the activity of matrix metalloproteinase-9 and the secretion of urokinas

59 T cells display helper function for monocyte matrix metalloproteinase-9 and tissue factor production

60 on of beta2GPI-specific T cells for monocyte matrix metalloproteinase-9 and tissue factor production,

61 mDCs; moreover, mDCs secreted high levels of matrix metalloproteinase-9 and upregulated C1q, heat sho

62 a 3- to 5-fold increased motility, invasion, matrix metalloproteinase-9 and vascular endothelial grow

63 ction of other tumorigenic factors including matrix metalloproteinase-9 and vascular endothelial grow

64 CD163(+) TAMs produced protumoral factors, matrix metalloproteinases 9 and 11 (MMP9 and MMP11), at

65 ability and bioactivity via the secretion of matrix metalloproteinases 9 and heparanase.

66 a secreted glycoprotein that binds to MMP-9 (matrix metalloproteinase 9) and protects it from degrada

67 egulated genes (interleukin (IL)-6, IL-8 and matrix metalloproteinase-9) and significantly decreased

68 cFLIP), proliferation (cyclin D1), invasion (matrix metalloproteinase-9), and angiogenesis (vascular

69 ess Sema3a induces dysregulation of nephrin, matrix metalloproteinase 9, and alphavbeta3 integrin in

70 O synthase (iNOS)), cell adhesion molecules, matrix metalloproteinase 9, and chemokine (RANTES).

71 As involved in these processes (e.g., Actin, matrix metalloproteinase 9, and cyclin D1 and B1).

72 levated mRNA and protein levels of IL-12p40, matrix metalloproteinase 9, and inducible NO synthase, w

73 molecule 1 [ICAM-1], myeloperoxidase [MPO], matrix metalloproteinase 9, and vascular cell adhesion m

74 or necrosis factor-alpha, interleukin-1beta, matrix metalloproteinase-9, and inducible nitric oxide s

75 n matrix-degrading proteases cathepsin S and matrix metalloproteinase-9, and systemic serum amyloid A

76 hway and by upregulating expression of CD44, matrix metalloproteinase-9, and the hyaluronan-mediated

77 protein-47 (markers of collagen synthesis), matrix metalloproteinase-9, and tissue inhibitor metallo

78 at the levels of matrix metalloproteinase-2, matrix metalloproteinase-9, and transforming growth fact

79 al ECs produced up to 61% less NO, IL-8, and matrix metalloproteinase-9, and up to 3-fold more activi

80 genase-2, intercellular adhesion molecule-1, matrix metalloproteinase-9, and vascular endothelial gro

81 ncode vascular endothelial growth factor and matrix metalloproteinase-9 are stabilized when murine ma

82 Up-regulation of matrix metalloproteinase-9 associated with astrocyte act

83 s of IgE and neutrophil-generated mediators, matrix metalloproteinase-9, B-cell activating factor, tr

84 ta1 promoted the expression and secretion of matrix metalloproteinase-9 by podocytes.

85 expression of the osteoclast genes encoding matrix metalloproteinase 9, cathepsin K, tartrate-resist

86 f inflammatory genes including CD68, leptin, matrix metalloproteinase-9, CD163, and CD8A were signifi

87 ues from symptomatic patients that comprised matrix metalloproteinase 9, chitinase 3-like-1, S100 cal

88 1.048 g/mL released higher levels of active matrix metalloproteinase 9 compared with cells from nons

89 atients also produced elevated quantities of matrix metalloproteinase 9, consistent with a capacity t

90 in-like growth factor binding protein-3, and matrix metalloproteinase-9 correlated with edema reducti

91 s desmin, fibroblast-specific protein-1, and matrix metalloproteinase-9 could be observed in glomerul

92 migration inhibitory factor (MIF), VEGF, and matrix metalloproteinase 9, creating a microenvironment

93 Various concentrations of matrix-metalloproteinase-9-digested Col-I fibers on NCsf

94 gh levels of matrix metalloproteinase-14 and matrix metalloproteinase-9 expressed by the wrapping ECs

95 tracellular matrix remodeling is mediated by matrix metalloproteinase-9 expressed in macrophages with

96 Increased invasion was mediated by matrix metalloproteinase 9 expression and activity in th

97 ltration, glutathione-synthesizing capacity, matrix metalloproteinase 9 expression and neointimal smo

98 This was associated with decreased matrix metalloproteinase 9 expression and reduced loss o

99 Neointimal SMC proliferation and medial SMC matrix metalloproteinase 9 expression were not altered b

100 rtas had decreased inflammatory cytokine and matrix metalloproteinase 9 expression.

101 Matrix metalloproteinase-9 expression was increased in B

102 diated targeting activated AKT and increased matrix metalloproteinase-9 expression.

103 vasion and migration associated with reduced matrix metalloproteinase-9 expression.

104 for C-reactive protein; prostaglandin E(2); matrix metalloproteinase-9; fibrinogen; endotoxin; inter

105 extend this work to show that in addition to matrix metalloproteinase 9, hypoxia-inducible factor 1al

106 nt decrease in the amount of neutrophils and matrix metalloproteinase 9 in the tissues, and the mitig

107 ssive breast cancers, including PKCdelta and matrix metalloproteinase-9 in both MCF-7-Ptn and NIH 3T3

108 e comparable in modulating the expression of matrix metalloproteinase-9 in bronchoalveolar lavage.

109 assay and alphavbeta6 mediated production of matrix metalloproteinase-9 in Calu-3 cells.

110 roduction, and release of neutrophil-related matrix metalloproteinase-9 in Ceacam1(-/-) mice were con

111 rkers of neurovascular remodeling, including matrix metalloproteinase-9 in GFAP-positive astrocytes a

112 IL-8 in turn controls the production of matrix metalloproteinase-9 in keratinocytes.

113 ted increases in the expression of Rho-A and matrix metalloproteinase-9 in LRs, and (3) Tat-mediated

114 This chemokine activated matrix metalloproteinase-9 in neutrophils, allowing thei

115 ed neutrophil oxidative burst and release of matrix metalloproteinase-9 in vitro.

116 a-2-macroglobulin or the hemopexin domain of matrix metalloproteinase 9) induces TrkC, Akt, and ERK a

117 uclear factor-kappaB activity, inhibition of matrix metalloproteinase-9 induction, the maintenance of

118 artery bypass graft-induced increased plasma matrix metalloproteinase-9, interleukin-6, and C-reactiv

119 Matrix metalloproteinase 9 is an inflammatory biomarker

120 Matrix metalloproteinase-9 is implicated in airway infla

121 The ability to accurately detect elevated matrix metalloproteinase 9 levels may lead to earlier di

122 Reducing the matrix metalloproteinase-9 levels by RNA interference in

123 In vitro, IL-20 upregulated matrix metalloproteinase-9, matrix metalloproteinase-12,

124 Matrix metalloproteinase 9, metalloproteinase inhibitor

125 Macrophages expressing matrix metalloproteinase-9 migrate to the deteriorating

126 ignificant increase in collagen degradation, matrix metalloproteinase 9 (MMP-9) activity and tissue d

127 action as well as tear collection to measure matrix metalloproteinase 9 (MMP-9) activity were perform

128 is was associated with decreased circulating matrix metalloproteinase 9 (MMP-9) and increased circula

129 ukin (IL) -12, IL-1 receptor antagonist, and matrix metalloproteinase 9 (MMP-9) and increased macroph

130 n revealed that it induces the expression of matrix metalloproteinase 9 (MMP-9) and MMP-13, both of w

131 Several lines of evidence have implicated matrix metalloproteinase 9 (MMP-9) as a protease inducin

132 Retinoic acid (RA) inhibits matrix metalloproteinase 9 (MMP-9) expression due to AP-

133 We reported previously that PGE2 induces matrix metalloproteinase 9 (MMP-9) expression in DCs and

134 4 antagonist, AMD also up-regulated VEGF and matrix metalloproteinase 9 (MMP-9) expression, and the b

135 in vivo, primarily through the inhibition of matrix metalloproteinase 9 (MMP-9) expression.

136 r the quantitation of the zinc endopeptidase matrix metalloproteinase 9 (MMP-9) from mouse serum.

137 We recently demonstrated that matrix metalloproteinase 9 (MMP-9) induces significant a

138 Matrix metalloproteinase 9 (MMP-9) is a critical mediato

139 Matrix Metalloproteinase 9 (MMP-9) is an enzyme involved

140 Matrix metalloproteinase 9 (MMP-9) is present in arteria

141 Expression of matrix metalloproteinase 9 (MMP-9) is up-regulated in os

142 Activation of matrix metalloproteinase 9 (MMP-9) paralleled injury, bu

143 Matrix metalloproteinase 9 (MMP-9) was selectively upreg

144 The expression of matrix metalloproteinase 9 (MMP-9) was suppressed when T

145 ar junctions concurrently with expression of matrix metalloproteinase 9 (MMP-9), a marker of fast MNs

146 Cathepsin B increased the activity of matrix metalloproteinase 9 (MMP-9), an enzyme involved i

147 kin-8 (IL-8), epidermal growth factor (EGF), matrix metalloproteinase 9 (MMP-9), and interleukin-1 be

148 at B. burgdorferi induces the host protease, matrix metalloproteinase 9 (MMP-9), and suggested that t

149 ed increased p308 and significant amounts of matrix metalloproteinase 9 (MMP-9), and these effects we

150 splayed a high level of enzymatically active matrix metalloproteinase 9 (MMP-9), and were capable of

151 autoimmune skin-blistering disease, involves matrix metalloproteinase 9 (MMP-9), IL-17, and IL-23 rel

152 n of adherens junctions through induction of matrix metalloproteinase 9 (MMP-9).

153 llagen I were reduced as was the activity of matrix metalloproteinase 9 (MMP-9).

154 cipal H3NT protease of osteoclastogenesis is matrix metalloproteinase 9 (MMP-9).

155 The involvement of matrix metalloproteinase-9 (MMP-9) activities in the dev

156 ed by increased proliferation, invasion, and matrix metalloproteinase-9 (MMP-9) activity (approximate

157 Uncontrolled increases of matrix metalloproteinase-9 (MMP-9) activity have been ca

158 Measurement of matrix metalloproteinase-9 (MMP-9) activity in the media

159 There is a well-documented association of matrix metalloproteinase-9 (MMP-9) and receptor Notch-1

160 showed significantly elevated expression of matrix metalloproteinase-9 (MMP-9) and reduced expressio

161 ion-on-chip (ChIP-on-chip) assay, identified matrix metalloproteinase-9 (MMP-9) as a direct target of

162 he objective of this study is to investigate Matrix Metalloproteinase-9 (MMP-9) as predictive biomark

163 tissue-type plasminogen activator (tPA) and matrix metalloproteinase-9 (MMP-9) can produce BBB damag

164 We previously demonstrated that matrix metalloproteinase-9 (MMP-9) contributes to the pa

165 We characterized a high matrix metalloproteinase-9 (MMP-9) expressing U1242 MG i

166 Matrix metalloproteinase-9 (MMP-9) expression is known t

167 nced ERK activation, motility, invasion, and matrix metalloproteinase-9 (MMP-9) expression relative t

168 IL-1beta has been reported to induce matrix metalloproteinase-9 (MMP-9) expression.

169 riptional activation of the matrix-degrading matrix metalloproteinase-9 (MMP-9) gene, a crucial media

170 An excessive amount of matrix metalloproteinase-9 (MMP-9) has been well documen

171 e have investigated the possible function of matrix metalloproteinase-9 (MMP-9) in alcohol addiction

172 addition to downregulating the expression of matrix metalloproteinase-9 (MMP-9) in hepatic IRI, CS-1

173 elevated expression of osteopontin (OPN) and matrix metalloproteinase-9 (MMP-9) in primary metastatic

174 Diabetes activates matrix metalloproteinase-9 (MMP-9) in the retina and its

175 We report that matrix metalloproteinase-9 (MMP-9) in the spinal cord co

176 Matrix metalloproteinase-9 (MMP-9) is a potent regulator

177 Matrix metalloproteinase-9 (MMP-9) is active in islets a

178 Matrix metalloproteinase-9 (MMP-9) is an extracellular p

179 Matrix metalloproteinase-9 (MMP-9) is important in numer

180 Activation of matrix metalloproteinase-9 (MMP-9) is involved in HIV-1-

181 Here we provide conclusive evidence that matrix metalloproteinase-9 (MMP-9) is necessary to the d

182 , leading to abdominal aortic aneurysms, and matrix metalloproteinase-9 (MMP-9) is the predominant en

183 Liver matrix metalloproteinase-9 (MMP-9) mRNA and MMP-2 mRNA w

184 ellular matrix-degrading enzyme gelatinase B/matrix metalloproteinase-9 (Mmp-9) on islet function in

185 Matrix metalloproteinase-9 (MMP-9) plays a critical role

186 Matrix metalloproteinase-9 (MMP-9) plays an important ro

187 Matrix metalloproteinase-9 (MMP-9) produced by colorecta

188 F) attenuate macrophage Tie-2 expression and matrix metalloproteinase-9 (MMP-9) production.

189 IVERSet chemical library for repressors of a matrix metalloproteinase-9 (MMP-9) promoter and identifi

190 The aim of this study was to combine matrix metalloproteinase-9 (MMP-9) protein (enzyme-linke

191 the mechanisms by which increased levels of matrix metalloproteinase-9 (MMP-9) protein causes myopat

192 Matrix metalloproteinase-9 (MMP-9) represents one of the

193 ate that Brucella abortus infection inhibits matrix metalloproteinase-9 (MMP-9) secretion and induces

194 ranscription factor 4 (Oct-4) expression and matrix metalloproteinase-9 (MMP-9) secretion by these ce

195 ta1), collagen deposition, and inhibition of matrix metalloproteinase-9 (MMP-9) secretion.

196 Matrix metalloproteinase-9 (MMP-9) synthesis is detected

197 Moreover, matrix metalloproteinase-9 (MMP-9) synthesis, which faci

198 osphatase staining, whereas the secretion of matrix metalloproteinase-9 (MMP-9) was measured by ELISA

199 tumor necrosis factor-alpha (TNF-alpha) and matrix metalloproteinase-9 (MMP-9) was performed on the

200 ith previous in vitro findings, the level of matrix metalloproteinase-9 (MMP-9) was reduced in MCP-1-

201 l mechanisms, the expression and activity of matrix metalloproteinase-9 (MMP-9) were evaluated by in

202 ontribute to neovascularization by supplying matrix metalloproteinase-9 (MMP-9), a protease that has

203 Matrix metalloproteinase-9 (MMP-9), a proteolytic enzyme

204 An mCherry fusion protein of matrix metalloproteinase-9 (MMP-9), a secreted glycoprot

205 We next determined whether matrix metalloproteinase-9 (MMP-9), an angiogenic factor

206 Recent studies indicate that matrix metalloproteinase-9 (MMP-9), an endopeptidase tha

207 tic receptor for diverse proteins, including matrix metalloproteinase-9 (MMP-9), and a cell-signaling

208 clin D1, matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), and cyclo-oxygenase-

209 Diabetes activates retinal matrix metalloproteinase-9 (MMP-9), and MMP-9 damages th

210 f an enzyme that is downstream of caspase-1, matrix metalloproteinase-9 (MMP-9), and protein levels o

211 LDD therapies in reducing gingival levels of matrix metalloproteinase-9 (MMP-9), interleukin-1beta (I

212 cell characteristics including secretion of matrix metalloproteinase-9 (MMP-9), invasion, and colony

213 One of these, matrix metalloproteinase-9 (MMP-9), is expressed only by

214 tion and reduced expression of Ki-67, COX-2, matrix metalloproteinase-9 (MMP-9), NF-kappaB p65, and V

215 molecules (VCAM-1 and ICAM-1, respectively), matrix metalloproteinase-9 (MMP-9), tumor necrosis facto

216 TGFbeta can induce expression of the matrix metalloproteinase-9 (MMP-9), which has critical r

217 eneration of the tissue remodelling protease matrix metalloproteinase-9 (MMP-9).

218 TIMP-1) is the major endogenous regulator of matrix metalloproteinase-9 (MMP-9).

219 acological inhibition or genetic ablation of matrix metalloproteinase-9 (MMP-9).

220 containing the cleavage site for the enzyme matrix metalloproteinase-9 (MMP-9).

221 e was in part modulated by the activation of matrix metalloproteinase-9 (MMP-9).

222 We report that matrix metalloproteinase-9 (MMP-9, extracellularly opera

223 tor-1 (SDF-1)/CXCL12 in the injured cord and matrix metalloproteinase-9 (MMP-9/gelatinase B), express

224 nd label-free detection of recombinant human matrix metalloproteinases-9 (MMP-9), which has been asso

225 rin and decreased expression and activity of matrix-metalloproteinase-9 (MMP-9) in the transfected ce

226 h a reduction in synthesis and activation of matrix metalloproteinase 9 (MMP9) and altered fibronecti

227 increased chondrocytic expression of Rankl, matrix metalloproteinase 9 (Mmp9) and Mmp13 and enhanced

228 n addition, they produce large quantities of matrix metalloproteinase 9 (MMP9) and promote vascular r

229 Matrix metalloproteinase 9 (MMP9) contributes to this pr

230 this oxidized and activated CaMKII promotes matrix metalloproteinase 9 (MMP9) expression in cardiomy

231 sed ventricular superoxide levels, increased matrix metalloproteinase 9 (Mmp9) expression, and reduce

232 (fgf8a) expression and positively regulates matrix metalloproteinase 9 (mmp9) expression.

233 Although matrix metalloproteinase 9 (Mmp9) has been implicated in

234 histoenzymology, and cathepsin B (CATB) and matrix metalloproteinase 9 (MMP9) immunochemistry.

235 hase 2 (Nos2), interleukin 1beta (Il1b), and matrix metalloproteinase 9 (Mmp9) in the gingiva; suppor

236 o a 7.0 +/- 1.6 (P < 0.05)-fold induction of matrix metalloproteinase 9 (MMP9) in the host lung.

237 Matrix metalloproteinase 9 (MMP9) is a member of a large

238 Matrix metalloproteinase 9 (MMP9) is a member of the MMP

239 Matrix metalloproteinase 9 (MMP9) is expressed in teeth

240 Here we show that matrix metalloproteinase 9 (MMP9) is involved in WNV ent

241 Matrix metalloproteinase 9 (MMP9) mRNA, which encodes a

242 hen recruits p38gamma as a cofactor into the matrix metalloproteinase 9 (MMP9) promoter to induce its

243 The relative expression of galectin-3 and matrix metalloproteinase 9 (MMP9) was evaluated by quant

244 Only matrix metalloproteinase 9 (MMP9) was validated; in pre-

245 n that chronic wounds exhibit high levels of matrix metalloproteinase 9 (MMP9), a key proteolytic enz

246 ignal-regulated kinase-1/2 (ERK1/2), AKT and matrix metalloproteinase 9 (MMP9), and inhibited the mot

247 nterleukin-1beta (IL-1beta), IL-6, CCL5, and matrix metalloproteinase 9 (MMP9), in addition to induct

248 Here, we show that levels of the matrix metalloproteinase-9 (MMP9) decrease, and the leve

249 Here we show that matrix metalloproteinase-9 (MMP9) deficiency causes phys

250 s long been implicated in virulence, induced matrix metalloproteinase-9 (MMP9) in epithelial cells ne

251 Inappropriate elevation of matrix metalloproteinase-9 (MMP9) is reported to be invo

252 ing growth factor-beta (TGF-beta) and active matrix metalloproteinase-9 (MMP9) were observed in media

253 ic inflammation and endothelial dysfunction (matrix metalloproteinase-9, myeloperoxidase, plasminogen

254 We observed upregulation of matrix metalloproteinase 9, N-cadherin, and fibronectin

255 ongruently identified abundance of CEACAM1(+)matrix metalloproteinase-9(+) neutrophils in the ischemi

256 ANK, TRAP, cathepsin K, calcitonin receptor, matrix metalloproteinase 9, NFATc1, DC-STAMP, ATP6v0d1,

257 g the expression of the tumorigenic proteins matrix metalloproteinase-9, nm23, urokinase plasminogen

258 doxorubicin, including improved response in matrix metalloproteinase-9 null mice that had increased

259 me and elevated basal expression of VEGF and matrix metalloproteinase-9 (P < 0.05).

260 4, suppressed the CypA-nuclear factor-kappaB-matrix-metalloproteinase-9 pathway in pericytes through

261 a proinflammatory CypA-nuclear factor-kappaB-matrix-metalloproteinase-9 pathway in pericytes.

262 interleukin-1b, interleukin-6, endothelin-1, matrix metalloproteinase-9, plasminogen activator inhibi

263 cell adhesion molecule 1, type IV collagen, matrix metalloproteinase 9, platelet-derived growth fact

264 d intensifies TNF-alpha, interleukin-12, and matrix metalloproteinase-9 production, all implicated in

265 outgrowth of early-stage tumors due to their matrix metalloproteinase-9 production, become dispensabl

266 We previously showed that pro-matrix metalloproteinase-9 (proMMP-9) binds to B chronic

267 deficiency leads to decreased activation of matrix metalloproteinase 9, reduced degradation of colla

268 MAPCs significantly decrease MMP-9 (matrix metalloproteinase-9) release from macrophages, ef

269 A 4-biomarker signature (matrix metalloproteinase 9, S100A8/S100A9, cathepsin D,

270 Furthermore, matrix metalloproteinase 9 secretion and activity were a

271 haride), concomitant with increased VEGF and matrix metalloproteinase 9 secretion.

272 CEACAM1 controls matrix metalloproteinase-9 secretion by neutrophils in p

273 ine the effect of recombinant osteopontin on matrix metalloproteinase-9, substrates of matrix metallo

274 aride on interleukin-12, interleukin-23, and matrix metalloproteinase-9, suggesting that the antivira

275 Matrix metalloproteinase 9 testing in DED is a valuable

276 n (cyclooxygenase-2) and matrix degradation (matrix metalloproteinase-9) that are known to be regulat

277 uld be attributed to changes in TGF-beta and matrix metalloproteinase-9, the downstream effectors of

278 ctor, selectins, inflammatory cytokines, and matrix metalloproteinase-9, the latter incriminated in b

279 itamin C also restricts the up-regulation of matrix-metalloproteinase-9, the major lung protease invo

280 chial artery, matrix metalloproteinase-2 and matrix metalloproteinase-9, tissue metalloproteinase inh

281 cytokine-induced neutrophil chemoattractant, matrix metalloproteinase 9, TNF-alpha, and IL-6.

282 Release of active matrix metalloproteinase 9, TNF-alpha, CXCL8, and IL-10

283 eptor kinase, interleukin-3, interleukin-13, matrix metalloproteinase-9 total, apolipoprotein E and i

284 exhibit a hyperinvasive phenotype (marked by matrix metalloproteinase-9 upregulation, faster invasion

285 educed expression of downstream target genes matrix metalloproteinase 9, urokinase plasminogen activa

286 This increase in matrix metalloproteinase-9 was associated with a higher

287 ion of FR-beta, mannose receptor, IL-10, and matrix metalloproteinase-9 was significantly increased i

288 Myeloperoxidase, D-dimer, and matrix metalloproteinase 9 were not modified.

289 es, the tight junction protein occludin, and matrix metalloproteinase-9 were among the key difference

290 Osteopontin and matrix metalloproteinase-9 were confirmed inside EV.

291 microglial activation and expression of pro-matrix metalloproteinase-9 were significantly increased

292 tor, chemokine (C-X-C motif) receptor 4, and matrix metalloproteinase 9, were more highly expressed i

293 well as inducible nitric oxide synthase and matrix metalloproteinase 9, were significantly decreased

294 ished through the action of gelatinases (eg, matrix metalloproteinase 9), which degrade collagen comp

295 d vascular cellular adhesion molecule-1, and matrix metalloproteinase 9), which represent surrogate i

296 racterized by endocytic markers, but also of matrix metalloproteinase 9, which is not associated with

297 ne array data revealed reduced expression of matrix metalloproteinase 9 with the ablation of either P

298 ell increase then led to the upregulation of matrix metalloproteinase 9, ZEB-1, CD133 and CXCR4 molec

299 on matrix metalloproteinase-9, substrates of matrix metalloproteinase-9 (zona occludens-1, laminin),

300 acrophages has long been attributed to their matrix metalloproteinase-9 zymogen (proMMP-9).